Souza Clarissa P, Rosychuk Rod A W, Contreras Elena T, Schissler Jennifer R, Simpson Andrew C
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Science, Colorado State University, 300 West Drake Road, Fort Collins, CO, 80525, USA.
Vet Dermatol. 2018 Dec;29(6):489-e164. doi: 10.1111/vde.12682. Epub 2018 Aug 23.
Lokivetmab neutralizes IL-31, a cytokine that plays an important role in the pathogenesis of atopic dermatitis (AD) in dogs.
To review experience of one year of treatment with lokivetmab for the control of pruritus in dogs with allergic dermatitis.
Eighty dogs diagnosed with AD, ten with concurrent adverse food reaction and AD and 45 with allergic dermatitis of undetermined cause. Three dogs were lost to follow- up.
Retrospective analysis of medical records of dogs with allergic dermatitis treated with lokivetmab from November 2015 to October 2016. Treatment success for owner-assessed pruritus was empirically defined as ≥2 cm reduction in Visual Analog Scale (pVAS) from baseline. A ≥50% reduction in pVAS also was recorded.
Pruritus improvement was achieved in 116 of 132 dogs (87.8%) following initial lokivetmab administration at 1.8 to 3.7 mg/kg (P < 0.001). A pVAS reduction of ≥50% was recorded in 104 dogs (77.0%). Dogs with severe/very severe pruritus prior to treatment and large/giant sized dogs, had 2.7 and 2.8 times higher odds of treatment success, respectively. There were no significant associations between treatment success and age of onset of clinical signs, disease chronicity, lokivetmab dosage or age at initial lokivetmab administration. Dogs that did not previously respond to oclacitinib were less likely to respond to lokivetmab. Adverse effects including lethargy, vomiting, hyperexcitability, pain at injection site and urinary incontinence were reported in 11 of 132 dogs.
Lokivetmab at labelled dosages was a fast, safe and efficacious therapy for the control of pruritus in dogs with allergic dermatitis.
洛维单抗可中和白细胞介素-31，白细胞介素-31是一种在犬特应性皮炎（AD）发病机制中起重要作用的细胞因子。
回顾使用洛维单抗治疗一年以控制过敏性皮炎犬瘙痒的经验。
80只被诊断为AD的犬，10只同时患有食物不良反应和AD，45只患有病因不明的过敏性皮炎。3只犬失访。
对2015年11月至2016年10月接受洛维单抗治疗的过敏性皮炎犬的病历进行回顾性分析。根据主人评估的瘙痒情况，治疗成功经验性定义为视觉模拟量表（pVAS）较基线降低≥2 cm。还记录了pVAS降低≥50%的情况。
132只犬中有116只（87.8%）在首次给予1.8至3.7 mg/kg洛维单抗后瘙痒得到改善（P < 0.001）。104只犬（77.0%）记录到pVAS降低≥50%。治疗前患有严重/非常严重瘙痒的犬以及大型/巨型犬，治疗成功的几率分别高出2.7倍和2.8倍。治疗成功与临床症状出现的年龄、疾病慢性程度、洛维单抗剂量或首次给予洛维单抗时的年龄之间无显著关联。先前对奥克拉替尼无反应的犬对洛维单抗有反应的可能性较小。1条犬出现嗜睡、呕吐、过度兴奋、注射部位疼痛和尿失禁等不良反应。
标签剂量的洛维单抗是控制过敏性皮炎犬瘙痒的快速、安全且有效的疗法。
